Description
Title: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias is Protein Kinase CK2
Abstract: Due to the impressive clinical responses obtained with BCRABL specific tyrosine kinase inhibitors, BCR-ABL-mediated leukemias, either Chronic Myeloid Leukemia (CML) or Philadelphia positive Acute Lymphoblastic Leukemia (ALL), are the model for targeted molecular therapy of cancer (TKIs). BCR-ABL TKIs do not, however, allow for the complete eradication of both ALL and CML. Additionally, treatment for ALL is linked to much worse TKI responses than those seen in CML. To achieve synthetic lethality in conjunction with TKI, additional pathways that mediate BCR-ABL leukemogenesis must be identified. Here, we discuss the function of the BCR-ABL/protein kinase CK2 interaction in BCR-ABL leukemias and discuss any potential therapeutic implications.
Paper Quality: SCOPUS / Web of Science Level Research Paper
Subject: Medicine
Sub Category: Hematology
Writer Experience: 20+ Years
Plagiarism Report: Turnitin Plagiarism Report will be less than 10%
Restriction: Only one author may purchase a single paper. The paper will then indicate that it is out of stock.
What will I get after the purchase?
A turnitin plagiarism report of less than 10% in a pdf file and a full research paper in a word document.
In case you have any questions related to this research paper, please feel free to call/ WhatsApp on +919726999915
Reviews
There are no reviews yet.